30.71
1.54%
-0.48
Finanzdaten der Collegium Pharmaceutical Inc-Aktie (COLL)
Gewinn- und Verlustrechnung
Vierteljährlich
*Alle Zahlen in Millionen
Enddatum des Zeitraums | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
Periodenlänge | 3 Monate | 3 Monate | 3 Monate | 3 Monate | 3 Monate |
Revenues |
3.22%
144.92
|
149.75 | 136.71 | 135.55 | 144.77 |
Cost Of Revenue |
2.99%
53.47
|
55.12 | 56.40 | 61.72 | 67.36 |
Gross Profit |
3.35%
91.46
|
94.63 | 80.31 | 73.83 | 77.40 |
Operating Expenses |
27.44%
41.98
|
32.94 | 35.30 | 38.19 | 52.77 |
Interest Income/Expense |
10.07%
17.34
|
19.28 | 20.77 | 21.86 | 21.43 |
Benefits Costs and Expenses |
5.11%
108.30
|
103.03 | 107.93 | 117.75 | 162.32 |
Costs And Expenses |
5.11%
108.30
|
103.03 | 107.93 | 117.75 | 162.32 |
Operating Income/Loss |
19.80%
49.47
|
61.69 | 45.01 | 35.63 | 24.63 |
Income/Loss From Continuing Operations Before Tax |
21.60%
36.62
|
46.71 | 28.78 | 17.80 | -17.56 |
Income Tax Expense/Benefit, Deferred |
1,205%
-4.412
|
-0.338 | -1.133 | -0.636 | -0.046 |
Income Tax Expense/Benefit |
39.68%
8.909
|
14.77 | 8.149 | 4.79 | -0.131 |
Income/Loss From Continuing Operations After Tax |
13.23%
27.71
|
31.94 | 20.63 | 13.01 | -17.43 |
Net Income/Loss
|
13.23%
27.71
|
31.94 | 20.63 | 13.01 | -17.43 |
Preferred Stock Dividends And Other Adjustments |
-
|
- | - | - | - |
Attributable To Noncontrolling Interest |
-
|
- | - | - | - |
Basic Average Shares |
0.08%
32.33
|
32.30 | 33.74 | 34.62 | 34.32 |
Diluted Average Shares |
0.38%
41.44
|
41.28 | 42.06 | 42.85 | 34.32 |
Basic Earnings Per Share |
13.13%
0.86
|
0.99 | 0.61 | 0.38 | -0.51 |
Diluted Earnings Per Share |
13.41%
0.71
|
0.82 | 0.53 | 0.34 | -0.51 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
-
|
- | - | - | - |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):